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Summary
Objective: To investigate the potential involvement of prostacyclin in basic calcium phosphate (BCP) crystal-induced responses in osteoar-
thritic synovial ﬁbroblasts (OASF).
Methods: OASF grown in culture were stimulated with BCP crystals. Prostacyclin production was measured by enzyme immunoassay. Ex-
pression of messenger RNA (mRNA) transcripts was assessed by real-time polymerase chain reaction (PCR). Expression of prostacyclin syn-
thase (PGIS) and the prostacyclin (IP) receptor was measured. The effects of iloprost, a prostacyclin analogue, on expression of genes
implicated in osteoarthritis such as microsomal prostaglandin E2 synthase 1 (mPGES1) and matrix metalloproteinases (MMPs) were also
studied. FPT inhibitor II, a farnesyl transferase inhibitor, was used to antagonize iloprost-induced responses.
Results: BCP crystal stimulation led to a ﬁve-fold increase in prostacyclin production in OASF compared to untreated cells. This induction was
attenuated by cyclooxygenase (COX)-2 and COX-1 inhibition at 4 and 32 h, respectively. PGIS and IP receptor transcripts were constitutively
expressed in OASF. BCP crystals upregulated IP receptor expression two-fold. While iloprost diminished BCP crystal-stimulated IP receptor
upregulation, the inhibitory effect of iloprost was blocked by the farnesyl transferase inhibitor. In addition, iloprost upregulated mPGES1 and
downregulated MMP-13 expression in BCP crystal-stimulated OASF, effects that were not inﬂuenced by the farnesyl transferase inhibitor.
Conclusions: These data showed for the ﬁrst time that BCP crystals can increase prostacyclin production and upregulate expression of the IP
receptor in OASF. The potential of prostacyclin to inﬂuence BCP crystal-stimulated responses was supported by the effects of iloprost on the
expression of the IP receptor, mPGES1 and MMP-13. These data demonstrate the potential involvement of prostacyclin in BCP crystal-as-
sociated osteoarthritis (OA) and suggest that inhibition of PG synthesis with non-steroidal anti-inﬂammatory drugs may have both deleterious
and beneﬁcial effects in BCP crystal-associated OA.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Basic calcium phosphate (BCP) crystals are predominantly
composed of partially carbonate-substituted hydroxyapatite,
but also include octacalcium phosphate and tricalcium
phosphate. BCP crystal deposition is associated with
a number of rheumatic syndromes including acute calciﬁc
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drome and osteoarthritis (OA) as well as non-rheumatic
syndromes such as breast cancer and atherosclerosis1,2.
The prevalence of BCP crystals in synovial ﬂuid from pa-
tients with knee OA is between 30 and 60%3e5, in contrast
to other destructive arthropathies such as rheumatoid arthri-
tis where they are rarely found. Ample data support the role
of BCP crystals in cartilage degeneration as their presence
correlates strongly with radiographic severity of OA6,7 and
larger joint effusions are seen in affected knee joints
when compared with joint ﬂuid from OA knees without crys-
tals8. In vitro properties of BCP crystals that may contribute
to OA pathogenesis include the induction of mitogene-
sis9,10, increased nitric oxide production11,12, upregulation
of tumor necrosis factor a (TNFa) and interleukin-1b
(IL-1b)13,14 and stimulation of matrix metalloproteinase4
415Osteoarthritis and Cartilage Vol. 15, No. 4(MMP) -1, -3, -8, -9, and -13 secretion10,15e18, which can
promote cartilage degradation.
It has been known for some time that BCP crystals cause
an increase in prostaglandin E2 (PGE2) production
16,19,20.
We have recently shown that this PGE2 induction is medi-
ated by upregulation of cyclooxygenase (COX)-2 and
COX-114,21. COX-2 expression and COX-2 derived PGE2
production were maximal at 4 h after stimulation with BCP
crystals, whereas COX-1 expression and COX-1 derived
PGE2 production was maximal at 32 h. Microsomal prosta-
glandin E2 synthase 1 (mPGES1) is generally upregulated
by inﬂammatory stimuli, is preferentially coupled with
COX-2 and is thought to be the key terminal PGE2 synthase
in inﬂammatory responses22. We have noted upregulation
of mPGES1 in human foreskin ﬁbroblasts (HFF) in re-
sponse to BCP crystal stimulation23, but not in osteoarthritic
synovial ﬁbroblasts (OASF)24. This discordance was attrib-
utable to downregulation of the EP4 receptor in OASF in re-
sponse to BCP crystals and was overcome by the addition
of exogenous PGE2. Therefore, although HFF have long
been used in the investigation of the in vitro effects of
BCP crystals and were considered comparable to synovial
ﬁbroblasts, we have noted differences in biological re-
sponses between HFF and OASF. As the latter are more
relevant from a pathophysiologic viewpoint, OASF were
used in this investigation.
Prostacyclin can contribute to hyperalgesia and vasodila-
tation in acute inﬂammation, modulate MMP expres-
sion25e27, promote angiogenesis28 and inﬂuence cell
proliferation in other settings29. Angiogenesis has been ob-
served in OA synovium30, with the synovium implicated as
the primary source of pro-angiogenic mediators. Angiogen-
esis has been proposed as a mechanism of cartilage loss in
OA31, and also plays a key role in the process of endochon-
dral ossiﬁcation that is involved in osteophyte forma-
tion31,32. Increased prostacyclin production has been
demonstrated in adjuvant-induced arthritis33,34. Prostacy-
clin has also been implicated in inﬂammatory and nocicep-
tive responses in animal models of inﬂammatory
arthritis35,36 and in exudate formation in a carrageenin-in-
duced pleurisy model in mice37. However, synovial ﬁbro-
blasts from patients with rheumatoid arthritis can produce
prostacyclin spontaneously38. In addition, rheumatoid and
non-rheumatoid synovial ﬁbroblast-like synoviocytes re-
lease prostacyclin (and PGE2) when incubated in condi-
tioned media from human peripheral blood mononuclear
cells39. The observed PG production was suppressed by
small doses of dexamethasone39.Prostacyclin production has not previously been reported
inOAsynovial tissues.Consequently, theexpressionof pros-
tacyclin synthase (PGIS) or that of the prostacyclin (IP) re-
ceptor therein has not been reported. We hypothesized that
BCP crystals increase prostacyclin production in OASF and
aimed to characterise the expression proﬁle of PGIS and
the IP receptor in OASF and to ascertain if their expression
is inﬂuenced by BCP crystal stimulation. We also examined
whether, in BCP crystal-stimulatedOASF, prostacyclin could
inﬂuence expression of mPGES1 and MMP-1, -3 and -13, all
of which have been implicated in OA pathogenesis.
Materials and methods
BCP CRYSTAL PREPARATION
BCP crystals were synthesized by alkaline hydrolysis of
brushite, as previously described40. Mineral prepared by
this method has a calcium/phosphate molar ratio of 1.59
and contains partially carbonate-substituted hydroxyapatite
as determined by Fourier transform infrared spectroscopy.
The crystals were weighed into vials and rendered pyro-
gen-free by heating at 200C for 90 min. The sterile crystals
were resuspended by brief sonication in Dulbecco’s modiﬁed
Eagles medium (DMEM) prior to use. Crystals were used at
a ﬁnal concentration of 18 mg/cm2 for all experiments.
CELL CULTURE
Synovial tissue was obtained from primary OA patients
undergoing joint replacement surgery. Informed consent
was obtained from all patients. Ethical approval was
granted by the National Orthopaedic Hospital Ethics Com-
mittee. The synovial tissue was minced and enzymatically
digested by 1.5 mg/ml collagenase in DMEM for 90 min at
37C. Then 0.5% trypsin in DMEM was added for a further
30 min incubation. Cells were centrifuged at 1000g for 5 min
and washed with phosphate-buffered saline/DMEM four
times. Cells were resuspended, grown and maintained in
DMEM containing 10% fetal bovine serum (FBS), 1% pen-
icillin/streptomycin/fungizone and 1% sodium pyruvate, in
a humidiﬁed incubator at 37C with 5% carbon dioxide/
95% air. All cultures used were fourth or ﬁfth passage cells.
Cells were rendered quiescent by incubation in media con-
taining 0.5% FBS for 24 h. Fresh 0.5% FBS containing me-
dia was then added and the cells treated with BCP crystals
or left untreated. All experiments were repeated at least
three times.Table I
Primer sequences for real-time PCR
Gene of interest Primer sequence (50/ 30) Tm ((C) Amplicon (bp)
IP Forward: CAC GAG GAG CAA AGC AAG TG 54 74
Reverse: AGG TCT GGG CTC TCC AGT CTT 56
PGIS Forward: AAA AGG CCA GGA TGA AAC TGA CT 53 102
Reverse: TCT GTA GCA TCG CCC AAC AG 54
mPGES1 Forward: CCT AAC CCT TTT GTC GCC TG 54 74
Reverse: CAG GTA GGC CAC GGT GTG T 55
MMP-1 Forward: GGG AGA TCA TCG GGA CAA CTC 56 79
Reverse: CAA TAC CTG GGC CTG GTT GA 54
MMP-3 Forward: AAGGATACAACAGGGACCAATTTATT 53 84
Reverse: CAGTGTTGGCTGAGTGAAAGAGA 55
MMP-13 Forward: CCA AAG GCT ACA ACT TGT TTC TTG 54 76
Reverse: AGG GTC CTT GGA GTG GTC AA 54
IP¼ prostacyclin receptor, PGIS¼ prostacyclin synthase, MMP¼matrix metalloproteinase, Tm¼ annealing temperature, bp¼ base pairs
(length of amplicon).
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Prostacyclin is unstable and rapidly converted to an inac-
tive, stable metabolite, 6-keto prostaglandin F1a (6-keto
PGF1a). Prostacyclin synthesis was assessed by measuring
6-keto PGF1a using a commercially available immunoassay
(R&D Systems; sensitivity 1.4 pg/ml). Quiescent OASF
were treated with aspirin (200 mM) for 30 min, rinsed with
PBS and fresh media containing 0.5% FBS added prior to
stimulation with BCP crystals (18 mg/cm2) for various times
between 4 and 32 h. The relative contributions of COX-1
and COX-2 to BCP crystal-stimulated 6-keto PGF1a produc-
tion were assessed using speciﬁc COX inhibitors: SC560
(COX-1) and SC236 (COX-2), and aspirin. Forty-ﬁve min-
utes prior to sample collection, cells were treated with
1 mM SC236, 1 mM SC560, 200 mM aspirin or left untreated.
Cells were rinsed and incubated in Hanks Hepes buffer with
50 mM arachidonic acid for 15 min at 37C. 6-Keto PGF1a
assays were carried out in duplicate at least three times.
REAL-TIME POLYMERASE CHAIN REACTION (PCR)
RNA extraction and reverse transcription were performed
as previously described14. Real-time PCR was carried out
using an ABI 7500 Sequence Detector (Applied Biosys-
tems, UK). Using SYBR green chemistry and 18S ribo-
somal RNA (18S) as an internal control, relative
quantitation of the amount of target copy in unknown sam-
ples is accomplished using the standard curve method. Se-
quences for the primers used are given in Table I. Primers
were used at a ﬁnal concentration of 300 nM. 18S primers
and probe mix, SYBR Green master mix and universal mas-
ter mix were purchased from Applied Biosystems and used
as per the manufacturer’s instructions.
STUDIES OF THE EFFECT OF PROSTACYCLIN IN OASF
Iloprost is a prostacyclin analogue that also has agonist ac-
tivity at the EP1 receptor. For the purposes of this investiga-
tion, this EP1 receptor agonism was not considered relevant
as there is negligible expression of EP1 in OASF41. There
is no established, commercially available compound that
acts as a speciﬁc IP receptor antagonist. However, a farnesyl
transferase inhibitor, FPT inhibitor II [disodium-(E,E )-2-
[2-oxo-2-[[(3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy]amino]
ethyl]phosphonic acid; Merck Biosciences], was used to an-
tagonize the effects of iloprost, as farnesylation of the IP re-
ceptor is required for its efﬁcient intracellular signaling42,43.
Iloprost and the FPT inhibitor II were used at concentrations
of 0.1 mg/ml and 1 mM, respectively; ethanol (0.1%) was
used as vehicle control.
STATISTICAL ANALYSIS
All quantitative data were expressed as mean standard
error of the mean (S.E.M.). Unpaired t tests were performed
using Microsoft Excel.
Results
BCP CRYSTALS INCREASE 6-KETO PGF1a PRODUCTION
IN OASF
Figure 1 demonstrates that BCP crystals stimulated an in-
crease in 6-keto PGF1a levels peaking at 4 h with a second
later peak at 32 h (approximately ﬁve-fold compared to un-
treated cells). The mean levels of 6-keto PGF1a productionin BCP crystal-stimulated OASF and untreated OASF were
283 39 pg/mg protein and 71 29 pg/mg protein, respec-
tively (mean S.E.M., n¼ 4). At 4 h, the increase in 6-keto
PGF1a was inhibited by addition of aspirin or the COX-2 se-
lective inhibitor SC236 (Fig. 2A). After 32 h, SC236 was no
longer a signiﬁcant inhibitor, but aspirin and the COX-1 se-
lective inhibitor SC560 equally inhibited 6-keto PGF1a pro-
duction (Fig. 2B).
EXPRESSION OF IP RECEPTOR AND PGIS IN OASF
IP and PGIS are constitutively expressed by OASF, as
measured by real-time PCR (data not shown). IP receptor
messenger RNA (mRNA) expression was upregulated ap-
proximately two-fold in OASF in response to BCP crystal
treatment for 24 or 32 h (Fig. 3). In contrast, expression of
PGIS mRNA in OASF was unchanged by treatment with
BCP crystals (data not shown).
ILOPROST MODULATES IP RECEPTOR AND mPGES1 mRNA
EXPRESSION
Administration of iloprost resulted in an approximate two-
fold reduction in IP receptor mRNA expression in BCP crys-
tal stimulated OASF, an effect that was antagonized by the
FPT inhibitor II (Fig. 4). Pre-treatment with the FPT inhibitor
II in the absence of iloprost resulted in a slight but signiﬁcant
(1.2-fold) upregulation of IP receptor mRNA expression
(Fig. 4). Addition of iloprost or the FPT inhibitor II did not
affect basal IP receptor expression in OASF not treated
with BCP crystals (data not shown).
Iloprost also resulted in a signiﬁcant induction of
mPGES1 mRNA expression in BCP crystal-treated OASF
(Fig. 5), which was not antagonized by the FPT inhibitor
II. A similar pattern of mPGES1 expression was seen in
OASF treated with iloprost and the FPT inhibitor II in the ab-
sence of BCP crystals (data not shown).
Fig. 1. BCP crystals stimulate increased prostacyclin production in
OASF. OASF were pretreated with aspirin (200 mm), a non-selec-
tive COX inhibitor, to investigate newly synthesized PGs. Cells
were then stimulated with BCP crystals and incubated for 4, 8, 24
or 32 h. Untreated controls were incubated for the same time inter-
vals. Cells were then incubated with arachidonic acid (50 mM) in
Hank’s Hepes buffer for 15 min. 6-keto PGF1a levels were mea-
sured (in duplicate) by enzyme immunoassay. Levels were ex-
pressed as fold change over the values obtained for the
untreated control incubated for the same period. Therefore, the un-
treated controls at each timepoint have a value of 1, and are not
shown (n¼ 3, mean S.E.M., *P< 0.05).
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Administration of iloprost resulted in an approximate
three-fold reduction in MMP-13 mRNA expression, an effect
that was not altered by the FPT inhibitor II (Fig. 6). Iloprost
treatment did not signiﬁcantly inﬂuence MMP-1 or MMP-3
mRNA expression in BCP crystal-stimulated OASF (results
not shown). Addition of iloprost or the FPT inhibitor II did not
affect basal MMP-13 expression in OASF not treated with
BCP crystals (data not shown).
Discussion
Our observations show for the ﬁrst time that prostacyclin is
produced by untreated OASF in the presence of arachidonic
acid and that PGIS and the IP receptor are constitutively
expressed in OASF. Furthermore, prostacyclin production
was augmented in OASF in response to BCP crystal
Fig. 2. Effect of COX inhibitors on BCP crystal-induced prostacyclin
production (A) at 4 h and (B) at 32 h. Cells were pretreated with as-
pirin (200 mm) and then incubated with BCP crystals for 4 h. Cells
were then treated with aspirin (B þASA, 200 mM), SC236
(BþSC236, 1 mM), SC560 (BþSC560, 1 mM) or left untreated
(B alone) for 30 min, then incubated with arachidonic acid
(50 mM) in Hank’s Hepes buffer for 15 min. 6-keto PGF1a levels
were measured (in duplicate) by enzyme immunoassay. Levels
were expressed as fold change over the values obtained for the cells
treated with BCP crystals alone, which therefore assumed a value of
1 (mean S.E.M., n¼ 3, *P< 0.05, **P< 0.01, ***P< 0.001).stimulation. BCP crystal-stimulated prostacyclin production
was mediated primarily by COX-2 at 4 h and COX-1 at
32 h. This is similar to the observed temporal pattern of
PGE2 production in response to BCP crystal stimulation,
and correlates well with the peak upregulation of COX-1
and COX-2 in response to BCP crystals14,21. Although
PGIS and the IP receptor are not generally regulated by in-
ﬂammatory stimuli, regulation of the IP receptor27 has previ-
ously been described. BCP crystal stimulation resulted in
a two-fold upregulation of IP receptor mRNA expression,
but did not inﬂuence PGIS expression. While this upregula-
tion of IP receptor mRNA expression was antagonized by
pre-treatment with iloprost, the inhibitory effect of iloprost
was overcome by a farnesyl transferase inhibitor. The upre-
gulation of the IP receptor byBCPcrystals is likely to augment
the responses to the prostacyclin that is produced in BCP
crystal-stimulated OASF, thereby potentially aggravating
the effects of prostacyclin in BCP crystal-associated OA.
Fig. 3. Expression of the IP receptor mRNA in OASF following stim-
ulation with BCP crystals. OASF were treated with BCP crystals
and incubated for 4, 8, 24 or 32 h. Untreated controls were incu-
bated for the same time intervals. IP receptor mRNA expression
was measured by real-time PCR, normalized to 18S values and
then expressed as fold change over the value obtained for the un-
treated control incubated for the same period. The untreated con-
trols therefore assumed a value of 1 and are not shown
(mean S.E.M., n¼ 3, *P< 0.05).
Fig. 4. Effect of iloprost on IP receptor mRNA expression. OASF
were treated for 32 h with BCP crystal with or without pre-treatment
with iloprost (ILO), FPT inhibitor II (FPT) or both for 30 min prior to
the addition of BCP crystals. mRNA expression was measured by
real-time PCR. Results were normalized to 18S values then ex-
pressed as fold change over values obtained for OASF treated
with BCP crystals alone, which therefore assumed a value of 1
(mean S.E.M., n¼ 3, *P< 0.05 vs BCP alone, #P¼ 0.05 vs BCP
alone, $P< 0.05 vs BCPþ ILO).
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prostacyclin production may modulate OASF responses to
BCP crystals. The downregulatory effect of iloprost on IP re-
ceptor expression may indicate the presence of a negative
feedback loop on prostacyclin function. However, at least in
BCP crystal-stimulated OASF, this negative feedback loop
does not appear to have the capacity to overcome the upre-
gulatory effect of BCP crystals on IP receptor expression.
The mPGES1 upregulation in response to iloprost suggests
the presence of a hitherto unsuspected crosstalk between
the terminal pathways leading to PGE2 and prostacyclin pro-
duction and emphasizes the complex regulation of the path-
ways leading to prostaglandin synthesis. Iloprost inhibited
Fig. 5. Effect of iloprost on mPGES1 mRNA expression. OASF
were treated for 32 h with BCP crystal with or without pre-treatment
with iloprost (ILO), FPT inhibitor II (FPT) or both for 30 min prior to
the addition of BCP crystals. mRNA expression was measured by
real-time PCR. Results were normalized to 18S values then ex-
pressed as fold change over values obtained for OASF treated
with BCP crystals alone, which therefore assume a value of 1
(mean S.E.M., n¼ 3, **P< 0.01).
Fig. 6. Effect of iloprost on BCP crystal-induced MMP-13 upregula-
tion. OASF were incubated with BCP crystals for 32 h, with or with-
out iloprost (ILO) with or without the farnesyl transferase inhibitor II
(FPT). MMP-13 mRNA expression was measured by real-time
PCR, normalized to 18S values and then expressed as fold change
over the value obtained for the sample treated with BCP crystals
alone. Therefore the samples treated with BCP crystals alone as-
sumed a value of 1 (mean S.E.M., n¼ 3, *P< 0.05, **P< 0.01
vs samples treated with BCP crystals alone).BCP crystal-stimulated MMP-13 expression, but did not affect
BCP crystal-induced MMP-1 or MMP-3 expression. There-
fore, the prostacyclin production observed in OASF in re-
sponse to BCP crystals may limit some of the deleterious
effects of BCP crystals on articular cartilage.
The possibility that the observed effects of iloprost on
mPGES1, IP and MMP-13 expression are mediated
through binding the EP1 receptor is unlikely given the
very low level of expression of this receptor in OASF41.
The inconsistent antagonistic effect of the FPT inhibitor
may indicate that different activities of the IP receptor may
differ in their dependence on IP farnesylation. As the phys-
iology of prostacyclineIP receptor signaling is still not well
understood, deﬁnitive characterization of the effects of pros-
tacyclin in OASF may require the commercial availability of
speciﬁc IP agonists and antagonists, or the use of other
techniques such as siRNA. The potential role of prostacy-
clin in OA certainly warrants further study, given its known
involvement in nociception and inﬂammatory responses
and potential to promote angiogenesis, modulate MMP
expression and contribute to cell proliferation25e29. In this
regard, it is interesting to note the putative role of angiogen-
esis in OA pathogenesis31.
Therefore, prostacyclin may have beneﬁcial as well as
deleterious effects in BCP crystal-associated OA. While
PGE2, the other major prostaglandin produced in OA joints,
has been shown to mediate IL-1b-associated cartilage deg-
radation in vitro44, it has also been shown to lead to reduced
cytokine production45e47 and diminished chemokine pro-
duction48e50. Inhibition of PG synthesis with non-steroidal
anti-inﬂammatory drugs (NSAIDs) is the most widely used
pharmacologic strategy for the treatment of OA. Many OA
patients will have associated intra-articular BCP crystal de-
position. While NSAIDs provide symptomatic relief, their
overall impact on OA disease progression is unclear. Al-
though the intricacies of the effects of PGs in OA remain
to be fully elucidated, these studies suggest that such
a broad, indiscriminate inhibition of PG production as that
provided by NSAIDs is unwise. Identiﬁcation of strategies
preferentially targeting the deleterious effects of PGs over
their beneﬁcial actions may result in more effective, poten-
tially disease-modifying, treatments for OA.
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